Kangpu Biopharmaceuticals has collaborated with Accelovance to start a Phase l trial of KPG-121 in combination with Enzalutamide to treat adult patients with metastatic castration-resistant prostate cancer (mCRPC).

The multi-centre, open-label trial has been commenced in the US, with plans to enrol around 24 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The three sites where the study will be conducted are part of Accelovance’s network of Helping Early Research in Oncology (HERO) sites, which are dedicated to early phase research in oncology.

The Phase l trial is designed to examine the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumour activity of KPG-121 and Enzalutamide combination in the enrolled patients.

“Kangpu expects to complete the trial by May 2020.”

The trial will be conducted in two parts. In part one, a 3+3 dose escalation phase is included to characterise the maximum tolerated dose (MTD) and a recommended Phase 2 dose (RP2D), while part two will be an expansion cohort at RP2D.

In addition, various escalating dose levels of KPG-121 such as 1.5mg, 3mg, 6mg, 11mg, 20mg, and 30mg a day in combination with enzalutamide will be investigated in part one to determine the MTD and RP2D of KPG-121.

An end-of-study (EOS)/early termination (ET) visit is also planned to be carried out within 14 days of the last dose of KPG-121, and a safety follow-up visit will be conducted in around 30 days after the last dose of KPG-121.

The trial will follow all the subjects for adverse events (AEs), serious adverse events, and concomitant medications for 30 days following the last dose of KPG-121.

Kangpu expects to complete the trial by May 2020.